- [Resource Hub](/) - [Publication](/?resource-type=publication#library) - Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma # Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma Adhikary P, Chakrabarti J, Wang J, Ezuma-Igwe U, Sun X, Bastian WC, et al. bioRxiv . 2025. DOI [10.1101/2025.05.22.655586](https://doi.org/10.1101/2025.05.22.655586). PMID 40661496. PMCID PMC12258720. How to cite ### AMA Adhikary P, Chakrabarti J, Wang J, Ezuma-Igwe U, Sun X, Bastian WC, et al. Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma. bioRxiv . 2025. doi:10.1101/2025.05.22.655586 ### APA Adhikary, P., Chakrabarti, J., Wang, J., Ezuma-Igwe, U., Sun, X., Bastian, W. C., et al. (2025). Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma. bioRxiv . https://doi.org/10.1101/2025.05.22.655586 ### BibTeX @article{adhikary2025spatial, title = {Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma}, author = {Adhikary, Pritha and Chakrabarti, Jayati and Wang, Jiang and Ezuma-Igwe, Ugonna and Sun, Xi and Bastian, Willian C. and others}, journal = {bioRxiv}, year = {2025}, doi = {10.1101/2025.05.22.655586}, pmid = {40661496} } Pancreatic ductal adenocarcinoma is among the deadliest cancers, with a 5-year survival rate below 10%, and chemotherapy often fails because the tumor's dense, immunosuppressive microenvironment shields resistant cells. Understanding that resistance means seeing which cells sit where inside the tumor, not just measuring the tumor as a whole. The team paired spatial imaging of treated and metastatic patient tissue with patient-derived organoid co-cultures that rebuild the microenvironment in a dish. Testing the drug cabozantinib alongside the immunotherapy pembrolizumab, they saw cancer cells die as immune-suppressing cells were depleted, yet a stubborn cancer stem cell population marked by CD44 variant 9 survived in both patient tissue and the lab models, pointing to a new therapeutic target. [Read publication at bioRxiv](https://pmc.ncbi.nlm.nih.gov/articles/PMC12258720/) ## Key findings - Spatial profiling exposed distinct cellular niches in metastatic PDAC. In metastatic liver tissue, the authors resolved niches of mesenchymal stem cells and fibroblasts (including myCAFs and iCAFs) alongside cancer stem cells expressing CD44 and TROP2. - Cabozantinib plus anti-PD-1 killed cancer cells and relieved immune suppression in organoid co-cultures. In patient-derived organoid co-cultures (PDO/CAF/IMM), cabozantinib combined with the anti-PD-1 antibody pembrolizumab enhanced cancer cell death by depleting myeloid-derived suppressor cells and promoted cytotoxic T lymphocyte proliferation. - A therapy-resistant CD44v9+ cancer stem cell population persisted across tissues and models. Across both patient tissues and treated co-cultures, a standard-of-care-resistant cancer stem cell population emerged that expressed CD44 variant 9 (CD44v9), nominating it as a candidate therapeutic target. ## Orion in the methods “The Rarecyte Orion™ multiplex immunofluorescence (MxIF) platform, capable of high-plex, high-throughput spatial profiling, was used to analyze human and mouse paraffin embedded (FFPE) tumor tissues and produce a comprehensive visualization of biomarker expression within the tumor microenvironment. Human tumor tissues were formalin fixed (3.7%), paraffin embedded (FFPE) and serially sectioned at a 5 micron thickness. Orion multiplex immunofluorescence was first performed using an 18-marker antibody panel in addition to Hoechst 33342.” — Adhikary et al., bioRxiv (2025), Methods, “Rarecyte Orion™ Multiplex Immunofluorescence” ## Why it matters for Orion users If you are weighing Orion for a tumor study, look at the job its multiplex immunofluorescence arm was given here. The question was not how much of a marker a tumor carries, but where specific cells sit inside an intact, treatment-scarred pancreatic tumor and its metastases. Orion carried the in-situ protein layer: an 18-marker antibody panel, plus a 14-marker panel, imaged on whole formalin-fixed sections at 20X, spanning tumor, immune, stromal and proliferation markers, so every cell keeps its position and its neighborhood. In those whole-slide images the authors localized CD44v9 marking the therapy-resistant cancer stem cells, SMA and vimentin marking fibroblasts and mesenchymal stem cells, and GFAP marking glial cells beside the tumor, read in place rather than dissociated. A paired spatial-transcriptomic readout and patient-derived organoid co-cultures did the wider cell-type census and the drug testing; Orion supplied the protein map, not the transcript layer. For your own work the takeaway is concrete: when a question turns on cellular neighborhoods in FFPE tissue you cannot dissociate, whole-slide multiplex immunofluorescence is the measurement that answers it. [Back to all resources](/#library) ## Related resources [Article](https://www.selectscience.net/article/advanced-spatial-biology-sheds-new-light-on-therapeutic-research) Orion SelectScience ### Advanced spatial biology sheds new light on therapeutic research [Read Article](https://www.selectscience.net/article/advanced-spatial-biology-sheds-new-light-on-therapeutic-research) [Article](https://www.selectscience.net/editorial-articles/bringing-spatial-biology-to-the-clinic-a-new-lens-on-cancer-biology/?&artID=58147) Orion SelectScience ### Bringing spatial biology to the clinic: “A new lens on cancer biology” [Read Article](https://www.selectscience.net/editorial-articles/bringing-spatial-biology-to-the-clinic-a-new-lens-on-cancer-biology/?&artID=58147) [Article](https://www.selectscience.net/article/how-to-unlock-the-complexity-of-tumor-microenvironments) Orion SelectScience ### How to unlock the complexity of tumor microenvironments [Read Article](https://www.selectscience.net/article/how-to-unlock-the-complexity-of-tumor-microenvironments) [Brochure](https://go.pardot.com/l/455452/2020-07-15/8p7453/455452/1606951069teslfZQe/BR21_101_Orion_Brochure_201202.pdf) Orion ### Orion Spatial Proteomics Platform [View Brochure](https://go.pardot.com/l/455452/2020-07-15/8p7453/455452/1606951069teslfZQe/BR21_101_Orion_Brochure_201202.pdf) [Spec Sheet](https://pardot.rarecyte.com/l/455452/2026-02-24/965v3w/455452/1771949067AeuR6syb/Orion_HT_spec_sheet.pdf) Orion ### Orion HT [View Spec Sheet](https://pardot.rarecyte.com/l/455452/2026-02-24/965v3w/455452/1771949067AeuR6syb/Orion_HT_spec_sheet.pdf) [Spec Sheet](https://pardot.rarecyte.com/l/455452/2025-10-31/961nyb/455452/1761933957WEJWJyeN/2025.07.14___SS___Orion__LE_.pdf) Orion ### Orion LE [View Spec Sheet](https://pardot.rarecyte.com/l/455452/2025-10-31/961nyb/455452/1761933957WEJWJyeN/2025.07.14___SS___Orion__LE_.pdf) [Spec Sheet](https://go.pardot.com/l/455452/2020-07-15/8p742r/455452/1607104572nfrlJouR/DF_24_101_201203_Orion_Datafile.pdf) Orion ### Orion [View Spec Sheet](https://go.pardot.com/l/455452/2020-07-15/8p742r/455452/1607104572nfrlJouR/DF_24_101_201203_Orion_Datafile.pdf) [Research Spotlight](/resources/spatial-profiling-immune-correlates-mss-crc/) Orion 2026 ### Spatial Profiling Uncovers Immune Correlates of Durable Response in Phase 1/2 MSS Colorectal Cancer Trial [Read Spotlight](/resources/spatial-profiling-immune-correlates-mss-crc/) [Publication](/resources/copanlisib-nivolumab-microsatellite-stable-colorectal/) Orion Nature Communications 2026 ### Copanlisib in combination with nivolumab for microsatellite stable colorectal cancer: a phase 1/2 trial [Read More](/resources/copanlisib-nivolumab-microsatellite-stable-colorectal/) [Publication](https://doi.org/10.1158/2159-8290.CD-26-0171) Orion Cancer Discovery 2026 ### Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution [View Publication](https://doi.org/10.1158/2159-8290.CD-26-0171) [Publication](https://www.nature.com/articles/s41467-026-74933-w) Orion Nature Communications 2026 ### Multiple human transgenes prolong survival of triple-carbohydrate knockout porcine kidney xenografts in nonhuman primates [View Publication](https://www.nature.com/articles/s41467-026-74933-w) [Video](https://www.youtube.com/watch?v=KOiToZIGN0g) Orion 2026 ### Dr. Tanjina Kader on mapping spatial proteomics and chromosomal changes on the same tissue section [Watch Video](https://www.youtube.com/watch?v=KOiToZIGN0g)